Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

ALS patient Steve Gleason attends an event to raise awareness about the disease

ALS patient Steve Gleason attends an event to raise public awareness about the fatal disease on February 10, 2013 in New Orleans, Louisiana. (Photo: Skip Bolen/Getty Images)

$158,000 Cost for ALS Treatment Called 'A Poster Child' for Unjust Drug Pricing

"The price of the newly approved drug combination Relyvrio to treat ALS," said one critic, "is yet another clear and powerful example of unjustified high prices set by drug companies that ultimately exploit patients."

Jake Johnson

Patient advocates on Tuesday condemned Amylyx Pharmaceuticals for setting the price of its newly FDA-approved ALS treatment at a staggering $158,000 a year, more than five times the top-line cost recommended by independent analysts.

Last week, the FDA formally approved Relyvrio to treat patients with amyotrophic lateral sclerosis, a progressive and rapidly fatal disease of the nervous system that currently affects tens of thousands of people in the United States.

"There is no justification for pricing Relyvrio, a drug that has not been proven effective, at $158,000."

Relyvrio, the first ALS treatment the FDA has approved in five years, is not a new drug but a combination of sodium phenylbutyrate and taurursodiol—a pairing that some research suggests can slow the disease's progression.

Personal anecdotes from ALS patients, many of whom celebrated the FDA's approval decision, also indicate the treatment can be effective, though the agency conceded that evidence for Relyvrio's effectiveness is still lacking.

A day after receiving approval from the FDA—which is barred from weighing the potential cost of a drug in its decision-making process—Amylyx announced an annual list price of $158,000 for Relyvrio. Experts at the Institute for Clinical and Economic Review, a nonprofit that analyzes medicine costs, published an assessment in August suggesting that Relyvrio should be priced somewhere between $9,100 and $30,600 per year assuming the treatment is effective.

"The price of the newly approved drug combination Relyvrio to treat ALS—a terrible neurological disease—is yet another clear and powerful example of unjustified high prices set by drug companies that ultimately exploit patients desperate for new treatments," David Mitchell, a cancer patient and president of Patients For Affordable Drugs, said in a statement Tuesday.

"This is not a new drug that required years of expensive, high-risk research in a lab; Relyvrio is a combination of two old drugs," Mitchell noted. "It was approved based on a small trial of 137 patients over 24 weeks, not an expensive, large, long study."

"There is no justification for pricing Relyvrio, a drug that has not been proven effective, at $158,000," he added. "It is a poster child for what is wrong with drug pricing in America and why our system must be reformed to arrive at appropriate prices that maximize accessibility and affordability for drugs that are shown to be both safe and effective."

Amylyx officials said during a conference call with investors last week that they expect insurers to absorb most of the costs of Relyvrio for ALS patients who opt to try the treatment—a claim that experts greeted with skepticism.

"We all pay for the premiums of our health plans," Stacie Dusetzina, an associate professor of health policy at Vanderbilt University Medical Center, told Politico.

"We're not talking about them setting a price to recoup their investments or anything like that," said Dusetzina. "This is basically taking advantage of the fact that we allow the price to be what the market will bear." Research published earlier this year found that roughly half of all new brand-name prescription drugs launched in the U.S. in 2020 and 2021 had an original price tag of at least $150,000 a year.

In addition to concerns about costs for ALS patients with commercial insurance, analysts have warned that Medicare Part D recipients who attempt to access Relyvrio "may be in for a significant cost-sharing burden."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

Right-Wing Extremist Boebert to Guide Policy on House GOP Leadership Team

"This is the Republican Party after a catastrophic midterm underperformance," said one Democratic strategist.

Julia Conley ·


Fonda's Fire Drill Fridays Returns to DC Streets Over Manchin Dirty Deal

"The time is now to vote out the politicians like Joe Manchin that are having the dirty deal perpetuated and who think that their pollution and their profits are more important than our lives," said White House adviser Jerome Foster II.

Brett Wilkins ·


House Committee to Investigate Alito Leak, Right-Wing Lobbying at Supreme Court

"It's clear that some of these justices are simply incapable of behaving ethically or putting the law before politics, and the court is unwilling or unable to police itself," said one court watchdog.

Julia Conley ·


Fetterman Taps Person Who Literally Wrote the Book on Killing Senate Filibuster as Chief of Staff

"It will be invaluable to have a veteran of the Senate and a veteran of state politics in these key positions as we serve the people of Pennsylvania," said the Senator-elect about two key hires for his new staff.

Jon Queally ·


Climate Activists Tell Macron to Stop Using Trade Rules to Thwart Clean Energy

"Governments should be empowered to fight climate change and support the clean energy transition without fear of being undermined by antiquated trade rules," said one advocate.

Kenny Stancil ·

Common Dreams Logo